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Summary Patient-guided management of asthma using adjustable dosing of
budesonide/formoterol in a single inhaler (Symbicorts) was compared with fixed
dosing in an open-label, multicentre, randomised study. Patients, uncontrolled on an
inhaled corticosteroid (ICS) or controlled on an ICS and a long-acting b2-agonist,
entered a 4-week run-in period and received budesonide/formoterol (80/4.5 or 160/
4.5 mg), 2 inhalations b.i.d. Following randomisation, the fixed-dosing group
(n ¼ 764) continued this regimen for a further 12 weeks. The adjustable-dosing
group (n ¼ 775) could step down to 1 inhalation b.i.d. if symptoms were controlled,
and, at early signs of worsening symptoms, promptly step up to 4 inhalations b.i.d.
for p2 weeks.
During run-in, National Heart, Lung and Blood Institute symptom-severity grading
was maintained in 60% and improved in 31% of patients, clinic peak flow increased
from 400 to 419 l/min (Po0:001), and health-related quality of life (overall
MiniAQLQ) improved from 4.6 to 5.4 (Po0:001). Patients effectively used the
adjustable-dosing regimen; 79% reduced budesonide/formoterol dosage and,
compared with fixed dosing, the number of inhalations were significantly lowered
(3.2 vs. 3.8 inhalations/day, Po0:05). Both regimens were well tolerated. In both
groups, symptom control was maintained or improved in 85–86% of patients, and 94%
experienced no treatment failures. Consistent with current guidelines, adjustable
maintenance dosing with budesonide/formoterol in a single inhaler provides
effective asthma control at reduced medication doses.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Asthma is a chronic inflammatory condition char-
acterised by variability of symptoms, airway cali-
bre, bronchial hyper-responsiveness and treatment
requirements; intermittent exacerbations can oc-
cur, which, if severe, can be life threatening.
National and international treatment guidelines
recognise the need to control asthma with the
lowest adequate doses of medication,1,2 with
inhaled corticosteroids (ICSs) established as the
cornerstone of treatment. Budesonide is a well-
established ICS that is effective and well tolerated
for maintenance treatment of asthma across a wide
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dose range (200–1600 mg daily3,4). Furthermore,
Foresi et al.5 demonstrated that, in patients taking
low-dose budesonide (100 mg twice daily), exacer-
bations could be effectively treated, at onset, by
temporarily increasing the dose of budesonide to
1000 mg/day for 7 days.
The introduction of long-acting b2-agonists (LA-
BAs) together with ICS, in asthma patients whose
symptoms are uncontrolled by ICS alone, is now
well established.1,2 Formoterol, added to inhaled
budesonide improves asthma symptom control to a
greater extent than increasing the dose of budeso-
nide alone in patients over a wide range of asthma
severity.6,7 Furthermore, budesonide together with
formoterol has been shown to be well tolerated at
high cumulative daily doses of 1920 and 54 mg,
respectively,8 and at conventional doses long
term.9 Formoterol has a rapid onset of action,
within 3min.10 It also produces dose-related
bronchodilatation at single doses over the range
of 6–48 mg.11
Guidelines advocate the use of written guided
self-management plans to allow patients to adjust
their own treatment in accordance with the level of
symptoms.1,2 Although guided self-management
has been shown to result in clinically important
improvements in asthma health outcomes,12 thor-
ough education and training of patients is required,
and clear action plans using effective therapies are
needed for success.13–15 However, the UK National
Asthma Campaign survey16 identified considerable
gaps in the information provided to patients when
asthma was first diagnosed, and very few patients
had written plans explaining when to take medica-
tion (6%) or what to do if asthma worsens (3%).
From a survey of 517 UK asthma patients, Haughney
et al.17 found that, although most patients (68%)
felt comfortable about adjusting the dose of their
inhaler without having to refer to a health profes-
sional, 81% had never been provided with a plan of
how they could change their medication in
response to varying symptoms.
Our hypothesis was that asthma can be effec-
tively controlled by increasing and decreasing the
dose of budesonide/formoterol, delivered twice
daily from a single inhaler, to an appropriate level
using a patient-driven self-management plan. The
study compared a regimen of adjustable dosing
with budesonide/formoterol in a single inhaler with
traditional, fixed, twice-daily dosing of the same
formulation in patients with asthma. The overall
clinical benefits of treatment were evaluated in
terms of the level of symptom control (treatment
success) using National Heart, Lung and Blood
Institute (NHLBI) definitions of symptom severity,18
and the proportion of patients experiencing treat-
ment failure. Additional comparisons between
treatments were made of health-related quality
of life (HRQoL), symptoms and lung function, and
tolerability. The study aimed to recruit a large and
diverse patient population suitable for ICS and
LABA treatment from a range of practices across
the UK, providing a robust assessment of the
clinical effectiveness of the adjustable-dosing
approach. This large study is the first to report
the use of a self-management regimen in patients
taking an ICS together with a LABA.
Methods
Study design
This randomised, open, parallel-group, multicentre
study was conducted in 365 general practice and
hospital centres across the UK. All patients initially
entered a 4-week run-in period on budesonide/
formoterol inhaler (Symbicorts Turbuhaler) 2 in-
halations twice daily (Fig. 1). Patients taking
budesonide 400 to o800 mg daily, or equivalent,
before study entry received the budesonide/for-
moterol 80/4.5 mg formulation and patients taking
budesonide 800–1600 mg daily, or equivalent, re-
ceived the budesonide/formoterol 160/4.5 mg for-
mulation. For this study, budesonide and
beclometasone dipropionate (BDP) by pressurised
metered-dose inhaler (pMDI) were considered of
equivalent potency on a microgram for microgram
basis. Because of the increased deposition of
budesonide administered by Turbuhaler compared
with pMDI, budesonide Turbuhaler doses were
considered equivalent to fluticasone and twice
those of BDP on a microgram for microgram basis.
At 2 inhalations twice daily, patients taking
budesonide/formoterol 80/4.5 mg received the
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Figure 1 Study design: All patients received fixed dosing
with budesonide/formoterol 80/4.5 or 160/4.5 mg 2
inhalations twice daily during the run-in and used the
same strength of inhaler throughout the study. The
dashed line indicates baseline at which patients were
randomised (R) to two treatment groups.
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same metered dose of budesonide (400 mg) and
formoterol (24 mg) daily as by separate Turbuhalers.
This also applied to patients taking higher strength
budesonide/formoterol 160/4.5 mg, i.e., metered
doses of budesonide 800 mg and formoterol 24 mg
daily by separate Turbuhalers. Patients remained
on the same strength of inhaler throughout the
study. Pre-study reliever medications were discon-
tinued and all patients used terbutaline sulphate
0.5mg/dose (Bricanyls Turbuhaler) as reliever
medication throughout the study.
PatientsX18 years of age, of either gender, were
included in the study if they had a clinical diagnosis
of asthma of at least 6 months duration, had been
receiving X400 mg/day ICS, at a fixed dose, for at
least 4 weeks, and budesonide/formoterol combi-
nation treatment was considered appropriate.
Patients were recruited with either a history of
previous stable symptom control taking an inhaled
LABA and an ICS (symptoms p2 days per week,
requiring p4 inhalations of reliever medication
weekly and having p2 nights with nocturnal
disturbance due to asthma in the previous month),
or evidence of sub-optimal control if receiving an
ICS and reliever medication alone (symptoms X2
days per week; or use X4 inhalations of reliever
medication per week; or X2 nights with nocturnal
asthma symptoms in the previous month; or a
forced expiratory volume in 1 s (FEV1) or peak
expiratory flow (PEF) o80% of predicted normal,19
if measured). Patients were excluded if they had
severe asthma (PEF o50% of predicted normal); or
were receiving regular treatment with high-dose
ICS (BDP or fluticasone propionate 42000 mg daily
or budesonide 41600 mg daily), or current oral
steroids, or nebulised therapy or b-blockers; or had
used oral steroids for more than 10 days in the
previous 3 months. Patients were also excluded if
they had been hospitalised twice or more with
asthma in the previous 12 months; or had suffered
an upper respiratory tract infection in the previous
4 weeks; or had other significant concomitant
diseases. Other exclusion criteria were habitual
overuse of b2-agonists, pregnancy, planning preg-
nancy or lactation.
Following the run-in, patients were randomised
to receive adjustable dosing (budesonide/formo-
terol 1–4 inhalations twice daily depending on
asthma symptoms) (Table 1) or fixed dosing
(budesonide/formoterol 2 inhalations twice daily)
for 12 weeks. Patients in the adjustable-dosing
group were instructed how to alter their therapy,
according to their level of symptoms.
Approval was obtained from a Multicentre Re-
search Ethics Committee and regional approvals
from Local Research Ethics Committees for the sites
involved in the study, and written informed consent
was obtained from all patients.
Efficacy assessments
Patients were assessed for efficacy parameters at
the beginning (visit 1) and end of the run-in (visit 2)
and after 4, 8 and 12 weeks of randomised
treatment. The patients completed diary cards
each day throughout the study.
The primary efficacy variables were the number
of treatment successes and treatment failures.
Treatment success was assessed by determining the
number of patients in each category of symptom
control according to NHLBI definitions18 (mild
intermittent, mild persistent, moderate persistent,
severe persistent; Table 2). Patients were allocated
to the most severe category for which they met at
least one criterion.
Treatment failure was defined as one or more of
the following: a serious asthma exacerbation
leading to use of non-study medication (excluding
a course of oral steroids lasting o5 days);
hospitalisation because of asthma deterioration;
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Table 1 Adjustable dosing: criteria for stepping up and stepping down.
Criteria for stepping up and stepping down
Step down from 2 to 1, or from
4 to 2, inhalations twice daily
If the patient was unaware of recent disease deterioration, including a
requirement for reliever medication on p2 days, and no night-time
awakening, because of asthma during the previous week
Step up to 4 inhalations twice
dailyn
If the patient had required reliever medicationX3 times during the day,
or had night-time awakening because of asthma on 2 consecutive days
nRegardless of the dose the patient was receiving at the time. If there was no improvement after 14 days, or if symptom control
deteriorated further, the patient was instructed to contact the investigator. A dose of 4 inhalations twice daily could be
maintained for more than 14 days at the discretion of the investigator. Patients were instructed not to use more than 8
inhalations daily without consultation with their physician.
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emergency treatment, such as nebulised b2-agonist
therapy or glucocorticosteroid injection; need for a
course of oral steroids lasting 5 or more days; or
lack of efficacy necessitating a change in asthma
medication and withdrawal from the study. For
patients in either group, two exacerbations requir-
ing additional treatment were allowed, but a third
exacerbation resulted in withdrawal from the
study.
Secondary efficacy variables derived from diary-
card data included morning and night-time PEF
measurements, asthma-free days, night-time awa-
kenings, use of reliever medication, daytime and
night-time asthma symptom scores (assessed by the
patient on a scale of 0 [defined as ‘no asthma
problems’] to 3 [defined as ‘asthma problems
prevent me from doing one or more activities’ or
‘asthma problems woke me up more than once in
the night and stopped me from sleeping’]) and
number of study drug inhalations. PEF was also
measured during each clinic visit.
At the beginning and end of the run-in and after
12 weeks of randomised treatment, patients
completed a self-administered Mini Asthma Quality
of Life Questionnaire (MiniAQLQ), with the overall
score calculated as the mean score of 15 ques-
tions.20 The MiniAQLQ comprises four domains,
activity (ability to carry out active tasks), symp-
toms (distress due to asthma symptoms), emotional
(emotional status) and environmental (symptoms
within certain environments). An increase in score
of 40.5 is considered indicative of a clinically
relevant improvement in HRQL.21
Safety assessments
The number, type and severity of adverse events
(AEs) were recorded throughout the study.
Statistics
Sample size was based on an estimate of there
being an average of 11% treatment failures in the
fixed-dosing group. This was estimated from the
FACET study6 in which 7% of patients on high-dose
budesonide had a severe exacerbation over 3
months, compared with 15% on low-dose budeso-
nide. In order to detect a clinically relevant
difference of 5%, e.g., 11% vs. 16%, with a power
of 80%, it was calculated that 733 patients per
group were required. It was aimed to enrol 1630
patients to allow for a 10% dropout during the run-
in period.
All patients who were enrolled at visit 1 and
received one dose of study drug were included in
the safety analysis. All patients who were rando-
mised and received at least one dose of study drug,
and for which efficacy data were recorded, were
included in the efficacy analysis. Between-group
comparisons of treatment failure and treatment
success were made using the Cochran–Mantel–
Haenszel test. Secondary efficacy variables were
summarised using descriptive statistics; the esti-
mated mean difference (and 95% CIs) between
groups for change from baseline (defined as the last
10 days of the run-in period) were calculated.
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Table 2 Definitions of asthma symptom severity (based on NHLBI, 1997)18.
Symptoms Night-time symptoms PEF
Severe persistent Continuous: limited
physical activity
Frequent p60% predicted
Variability430%
Moderate persistent Daily: use b2-agonist
daily
41 time a week 460% to o80%
predicted
Attacks affect activity Variability430%
Mild persistent X1 time a week but
o1 time a day
42 times a month X80% predicted
Variability: 20–30%
Mild intermittent o1 time a week
asymptomatic and
normal PEF between
attacks
p2 times a month X80% predicted
Variability o20%
PEF¼peak expiratory flow.
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Analysis of HRQL was based on a published
method.20
Results
Of the 1719 patients who were recruited to the run-
in period, a total of 1553 patients were randomised
to receive treatment, and of these, 1539 received
at least one dose of randomised treatment (775
adjustable dosing, 764 fixed dosing) and were
included in the efficacy analysis. Reasons for non-
randomisation were: AEs (n ¼ 61), non-eligibility
(n ¼ 16), lack of therapeutic response to budeso-
nide/formoterol (n ¼ 25) and loss during run-in
(n ¼ 21); and miscellaneous (n ¼ 43).
Demographic and clinical characteristics were
similar for the two randomised-treatment groups
(Table 3). Ninety-eight per cent of patients (both
groups) were Caucasian. The distribution of pa-
tients according to severity of asthma symptoms
was also similar; almost half of the patients had
moderate-persistent symptoms at enrolment, with
6% having severe-persistent symptoms. Duration of
asthma was41 year in 97% of the patients and45
years in 76% of the patients. The majority of
patients in both groups received BDP as the pre-
study ICS (58% adjustable dosing, 55% fixed dosing);
68% overall had been using pMDIs. Prior to the
study, 39% of patients in the adjustable-dosing
group and 42% in the fixed-dosing group were taking
a LABA. Asthma was less severe in patients who
received budesonide/formoterol 80/4.5 mg than
those receiving 160/4.5 mg during the randomised-
treatment phase of the studyF56% of patients
allocated 80/4.5 mg at visit 1 were classified as
having mild-intermittent or mild-persistent asthma
symptoms compared with 41% of patients allocated
160/4.5 mg.
Efficacy results during the run-in period
At the end of the run-in (visit 2), after 4 weeks of
treatment with budesonide/formoterol 2 inhala-
tions twice daily, 31% of all patients showed an
improvement in asthma symptom control compared
with visit 1 (Fig. 2). There was a significant overall
improvement in severity status for patients
(Po0:001 Wilcoxon’s signed-rank test), with a
greater proportion of patients (32% vs. 18%)
categorised with mild-intermittent symptoms and
fewer with severe- or moderate-persistent asthma
(37% vs. 52%). The majority of shift in severity was
from moderate- to mild-persistent or mild-inter-
mittent asthma, and from mild-persistent to mild-
intermittent asthma. This improvement in asthma
symptom severity status was also reflected in the
mean overall MiniAQLQ score, which increased
during the run-in from 4.6 (7SD 1.2) to 5.4 (7SD
1.1) (Po0:0001). There were clinically important
improvements in the means of all four domains of
the MiniAQLQ; activity from 5.2 (7SD 1.3) to 5.8
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Table 3 Demographic and clinical characteristics at randomisation.
Adjustable dosing Fixed dosing
Number of patients 782 771
Male/female 299/483 315/456
Mean age (years) 48.7 48.0
Range 1887 1881
Mean clinic PEF (l/min)n (SD) 416 (113) 423 (119)
80/4.5 mg 433 (114) 439 (117)
160/4.5 mg 403 (110) 411 (119)
Use of SABA for symptom relief during the run-in (% days) 44 46
80/4.5 mg 40 44
160/4.5 mg 47 47
Mean pre-study ICS dosew (mg) 674 670
Pre-study LABA;n patients; (%) 302 (39)z 323 (42)z
Budesonide/formoterol inhaler; patients; (%)
80/4.5 mg 337 (43) 331 (43)
160/4.5 mg 445 (57) 440 (57)
PEF¼peak expiratory flow, ICS¼ inhaled corticosteroids, SABA¼ short-acting b2-agonist, LABA¼ long-acting b2-agonist.
nn ¼ 775 and 764 for the adjustable- and fixed-dosing groups, respectively.
wn ¼ 772 and 755 for the adjustable- and fixed-dosing groups, respectively.
zIncludes LABA and combination ICS/LABA products.
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(7SD 1.2) (Po0:0001); symptoms from 4.4 (7SD
1.2) to 5.3 (7SD 1.2) (Po0:0001); emotional from
4.3 (7SD 1.6) to 5.2 [7SD 1.5] (Po0:0001);
environment from 4.4 [7SD 1.4] to 5.1[7SD 1.4]
(Po0:0001). Mean clinic PEF also increased clini-
cally and statistically significantly from 400 to
419 l/min during the run-in period (Po0:001).
Results for the randomised-treatment
comparison
Ability of patients to use self-management plan
In the adjustable-dosing group, most patients (604,
79%) reduced the dose of their medication at some
point during the randomised period; 69% and 53%
used 2 inhalations/day or less for at least 7 and 28
consecutive days, respectively. Of the patients who
reduced their dose of study medication, 121 (20%)
had one or more dosage increases during the
randomised-treatment period. Overall, 217 (28%)
of patients increased their dosage to 8 inhalations/
day at least once during the randomised period;
with 111 of these stepping up only once; the
median length of step up was 10 days. On average,
patients recorded that they used 2 inhalations/day
or less of study medication for half of the
randomised-treatment period.
Efficacy results
For the majority of patients in both groups (86–
87%), the level of asthma symptom control
achieved during the run-in was either maintained
or improved during the randomised period (Fig. 2).
The symptom severity levels in the adjustable- and
fixed-dosing groups were improved in 29% and 28%,
respectively, and maintained in 57% in both dosing
groups. At the end of the study, a greater
proportion of patients in both groups were cate-
gorised with mild-intermittent symptoms (39% vs.
30%) and fewer patients were categorised with
severe- or moderate-persistent symptoms than at
randomisation (29% vs. 38%).
In both treatment groups, 94% of patients did not
experience a treatment failure (Fig. 3) with the
most common reason for treatment failure in both
treatment groups being a need for a course of oral
steroids lasting 5 or more days. Only 2% of patients
in the adjustable-dosing group and 3% of patients in
the fixed-dosing group withdrew from the study
because of treatment failure. There was no
significant difference in the proportion of patients
experiencing treatment failures within each group
for patients receiving 80/4.5 or 160/4.5 mg bude-
sonide/formoterol.
Secondary measures
Secondary efficacy variables either improved
slightly or were relatively stable during the
randomised-treatment period (Table 4). Patients
in both treatment groups showed a higher propor-
tion of asthma-free days and fewer nocturnal
awakenings compared with the run-in period. The
improvements in symptom scores and MiniAQLQ
score observed during the 4-week run-in were
maintained throughout the randomised-treatment
period in both groups (Table 4), with no differences
between the groups.
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Figure 2 The proportion of patients showing improvement or worsening of asthma during the run-in (weeks 4–0) and
randomised-treatment period (weeks 0–12), as indicated by a change in asthma symptom severity level as defined by
NHLBI guidelines.18
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The overall improvement in PEF observed
during the run-in was maintained in both arms
after randomisation; both morning and evening
PEF (recorded by patients) increased in the fixed-
dosing group by approximately 2 l/min, and de-
creased in the adjustable-dosing group by a similar
amount. Although there were statistically signifi-
cant differences in the change in morning and
evening PEF during the randomised-treatment
period (4–5 l/min), this difference was very small
(1% baseline). Furthermore, there was no signifi-
cant difference between the two groups in clinic-
measured PEF during the randomised-treatment
period.
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Figure 3 The proportion of patients not experiencing treatment failure during the randomised treatment phase of the
study. Reasons for treatment failure are shown along the x-axis.
Table 4 Secondary efficacy variables: changes from baseline (last 10 days of run-in) to endpoint (week 12).
Adjustable dosing
(mean)
Fixed dosing (mean) Difference in change
between groups
(adjustable minus
fixed)w
Baseline Change at
endpoint
Baseline Change at
endpoint
(Mean and 95%
confidence intervals)
Asthma-free days (%) 45.3 3.2 43.7 3.4 0.2 (–2.6, 3.0)
Nights with nocturnal
awakenings (%)
8.5 1.1 9.7 0.9 –0.7(–1.9, 0.4)
Use of reliever medicationz 1.1 0.2 1.2 0 –0.2 (–0.3, –0.1)*
Reliever-free days (%) 64.0 1.9 61.8 2.2 0.5 (–2.4, 3.4)
Average total symptom
score
0.8 0.0 0.8 0.1 0.0 (0.0, 0.1)
Mean MiniAQLQ score 5.4y 0.0 5.4y 0.0 0.0 (–0.1, 0.0)
Mean morning PEF (l/min) 390 2.0 393 2.7 –4.8 (–8.0, –1.7)**
Mean evening PEF (l/min) 395 2.3 397 1.7 –4.0 (–7.1, –0.9)**
*Po0:05 in favour of adjustable-dosing group vs. fixed-dosing group.
**Po0:05 in favour of fixed-dosing group vs. adjustable-dosing group.
PEF¼peak expiratory flow, MiniAQLQ¼Mini Asthma Quality of Life Questionnaire.
wBased on ANCOVA model, which included terms for treatment group and strength of budesonide/formoterol inhaler.
zAverage inhalations/day.
yBaseline values were obtained from the questionnaire completed at visit 2.
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Doses of budesonide/formoterol and reliever
medication
The mean number of inhalations/day of budeso-
nide/formoterol over the course of the randomised
period was lower in the adjustable-dosing group
than in the fixed-dosing group (3.2 vs. 3.8,
respectively; Po0:05) (Fig. 4); the mean daily ICS
dose was 77 mg lower with adjustable dosing during
the last 7 days of treatment. The reduction of
inhaler use in the adjustable-dosing group occurred
mainly during the first 4 weeks of the randomisa-
tion period; thereafter the dose was maintained at
a similar level. In addition to the reduction in
budesonide/formoterol use in the adjustable arm,
this group also used 0.2 fewer doses of reliever
medication each day than the fixed-dosing group
(Table 4). The reliever use in the 604 patients who
succeeded in stepping down their dose was 0.74
inhalations per 24 h, and 0.22 (95% CI 0.09–0.35,
P ¼ 0:001) less than in the fixed-dosing group. Of
the patients who reduced their dosage of study
medication, 95% did not experience a treatment
failure during the 12-week randomised period, and
84% had an improvement in, or maintained, their
asthma symptom control.
Safety results
Budesonide/formoterol treatment was well toler-
ated. During the run-in, 32% of patients experi-
enced AEs and 4% discontinued because of AEs
(Table 5). There were two deaths (myocardial
infarction; congestive heart failure and coronary
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Figure 4 Mean number of inhalations per day of
budesonide/formoterol in the adjustable- and fixed-
dosing groups. The dashed vertical line indicates baseline
at which patients were randomised to the two study
groups. wmean daily budesonide dose.
Table 5 Adverse events (AEs) during the study.
n (%) of patients with: Run-in period
(weeks 4 to 0)
Randomised period (weeks 0–12)
All treated patients
(n ¼ 1719)
Adjustable dosing
(n ¼ 782)
Fixed dosing
(n ¼ 771)
AE 555 (32) 448 (57) 440 (57)
Serious AE 25 (1) 24 (3) 28 (4)
Fatal serious AE 2 (o1) 0 0
AE leading to
discontinuation
67 (4) 15 (2) 19 (2)
Due to asthma
aggravation
15 (o1) 6 (o1) 8 (1)
Most frequently
reported AEs
Upper respiratory
tract infection
27 (2) 61 (8) 42 (5)
Respiratory infection 22 (1) 51 (7) 47 (6)
Common cold 29 (2) 48 (6) 45 (6)
Headache 59 (3) 40 (5) 39 (5)
Asthma aggravation 21 (1) 33 (4) 35 (5)
Sore throat 38 (2) 27 (3) 24 (3)
Cough 20 (1) 20 (3) 17 (2)
Accident and/or
injury
6 (o1) 14 (2) 20 (3)
Coryza 5 (o1) 12 (2) 14 (2)
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insufficiency) during run-in; neither was consid-
ered, by the investigators, to be related to
treatment.
During the randomised-treatment period, there
were no significant differences between groups in
the incidence of AEs (57% both groups), serious AEs
(4% fixed dosing, 3% adjustable dosing) or disconti-
nuations arising from AEs (2% both groups) (Table 5).
The types of AEs reported throughout the study
were similar in both groups and within patients
using the 80/4.5 or 160/4.5 mg formulation. The
most frequently reported serious AE was asthma
aggravation (17/24 serious AEs in the adjustable-
dosing group, 17/28 in the fixed-dosing group); of
these events, six and eight led to withdrawal.
Discussion
The present randomised, controlled study is the
first to examine the effect of a symptom-driven,
self-management plan in a large asthma population
receiving budesonide/formoterol in a single inhaler
(Symbicorts). Patients were recruited from a large
number of general practices and hospital clinics,
and represented a diverse group in terms of
severity status and therapy at entry into the study.
This study demonstrated that patients were able to
adjust their treatment over a four-fold dose range
using a simple asthma action plan. Furthermore, in
comparison with traditional, fixed twice-daily dos-
ing, adjustable dosing was as effective in terms of
symptom severity, treatment failures, and second-
ary efficacy variables, which included clinic PEF,
asthma-free days, nocturnal awakenings, symptom
scores, MiniAQLQ, and morning and evening home
PEF. Adjustable dosing led to reduced usage of
combination therapy resulting in a 16% reduction in
inhaled steroid consumption. Unexpectedly, in-
haled b2-agonist reliever usage was also reduced
to a statistically significant degree (0.2 inhalations/
day) in the adjustable-treatment arm compared
with fixed dosing. Such reduced medication usage
can be expected to result in reduced healthcare
costs.
The present study incorporated a pragmatic,
open-label design to reflect normal clinical practice
as far as possible. This was selected in preference
to a double-dummy, placebo-controlled design,
which would have significantly complicated the
nature of the study. Patients were recruited from a
large number of general practices and hospital
clinics; this makes the results generalisable to
patients with a range of asthma severity, on various
treatments, from different clinical settings in
different parts of the country. To ensure quality
control across the large number of participating
centres, there were training sessions before and
during the study and regular monitoring, inspection
and audit visits during the study. Compliance was
not directly measured other than by recording of
inhalations taken (on diary cards). Patients in the
twice-daily fixed-dosing arm recorded taking an
average of 3.8 inhalations daily compared with the
prescribed 4.0 inhalations daily. A very small
proportion of patients recorded 0 inhalations over
short periods reflecting relatively low levels of
patient non-adherence, as expected in a clinical
trial of this nature.
Although a mix of uncontrolled (59%), and
controlled (41%) patients entered the study on an
ICS plus a short-acting b2-agonist (SABA) reliever or
an ICS plus a maintenance LABA, respectively, both
types of patients responded well to the 4-week
fixed-dose, twice-daily treatment with budeso-
nide/formoterol in a single inhaler. Overall, symp-
tom severity was maintained in 60% and improved
in 31% of patients, which was also reflected in a
clinically relevant improvement in QoL and PEF,
representing greater effectiveness of the study
treatment compared with pre-trial medication.
While this improvement may be related to better
adherence with therapy within a clinical trial,
the results are consistent with other clinical
studies in which formoterol was added to an ICS
in adult patients with asthma.6,7 This suggests that
an appropriate patient group was selected for
study.
Following randomisation, overall asthma control
was maintained to an equivalent degree in both
treatment groups; only 6% of patients from each
group experienced a treatment failure during the
12-week treatment period. The success of budeso-
nide/formoterol was also reflected in the overall
shift to a lower asthma symptom severity status
during the study, with the majority of the shift from
moderate- to mild-persistent or mild-intermittent
asthma. The initial improvements in asthma symp-
toms, QoL and peak flow observed during the run-in
period were also maintained in both groups follow-
ing randomisation. A small, but statistically sig-
nificant, reduction in morning and evening PEF was
seen in the adjustable-treatment arm compared to
the control group; however, the difference be-
tween groups (4–5 l/min, about 1% of baseline) is
not clinically meaningful. In addition, treatment
success and failure in patients in the adjustable-
dosing group who reduced their dosage of study
medication were similar to those for the whole
population, suggesting that adjustable dosing did
not compromise asthma control.
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Patients successfully managed the adjustable-
dosing regimen using a single combination inhaler:
the majority were able to step up and step down
their dose of budesonide/formoterol in response to
typical variations in their symptoms. This treat-
ment approach could be convenient for patients
and physicians and may minimise the need to visit
the doctor for additional prescriptions.
Interestingly, patients who reduced budesonide
and formoterol in the adjustable-dosing group also
used less reliever medication, suggesting that the
use of an asthma action plan, based on adjustable
dosing, is an appropriate strategy for optimising
therapy. The efficacy and tolerability of budeso-
nide/formoterol in a single inhaler observed in this
study was consistent with previous studies evaluat-
ing this inhaler in patients with both mild and more
severe asthma8,9,22,23 as well as extensive previous
experience with the two separate component
drugs.
A potential limitation of using this subjective
self-assessment of symptoms to guide dosage
adjustment, is that it did not include an objective
PEF measurement, although the value of including
lung function within a pragmatic action plan where
patient’s reported symptoms dictate management
is debatable.24–26 Furthermore, improvement in
patient-based outcome measurements including
MiniAQLQ has been shown to be more sensitive
than conventional measures of asthma control
including PEF and SABA use in a recent study of
two formulations of BDP inhalers.27 In the present
study, improvements in MiniAQLQ observed during
the run-in were maintained throughout the study.
Exacerbation rates were similarly low (6%) in both
treatment groups, suggesting that the action plan,
used for guiding adjustment of budesonide/formo-
terol dose, was clinically appropriate for this
patient group.
One interpretation of our data is that the
benefits of adjustable dosing over fixed dosing
were achieved because of overtreatment of pa-
tients in the fixed-dosing group. However, all the
patients entering the study satisfied the criteria
according to national and international guidelines
for treatment with ICS and LABA, indeed 41% of
patients were already receiving LABA, making the
question of dosage adjustment particularly appro-
priate. The marked improvement in asthma control
achieved during the run-in on a fixed dose of
budesonide/formoterol treatment further justified
the use of ICS and LABA in these patients. The
question addressed by the study was how adjus-
table dosing, using the adopted self-management
plan, would compare with traditional fixed twice-
daily dosing. Randomisation ensured that patients
who might or might not benefit from a reduction in
dose were evenly distributed between treatment
groups. The pattern of dosage adjustment seen in
the study, indicated that many of the patients were
not, in fact, overtreated. During the 3-month
treatment period, 21% of patients did not meet
the criteria for reducing dose and overall 28%
stepped up their dose to 8 inhalations daily at least
once. Furthermore, of the 79% of patients on
adjustable dosing who stepped down during the
study, 20% stepped up at least once during the
study.
Successful asthma management relies on estab-
lishing a partnership between the patient and
healthcare professional(s); the aim is to provide
the necessary and appropriate education, support,
medication and action plans to enable patients to
effectively control their own condition.1 The value
of guided self-management is supported by the
present large study and previous smaller studies
that have shown benefits for asthma self-manage-
ment plans.12,13,28,29 Apart from the present
clinical trial programme, we are unaware of other
studies of self-management in patients taking a
LABA. This strategy needs formal comparison with
others aimed at reducing individual components of
combination therapy ICS and/or LABA but no
validated schemes have been published as yet.
It might be argued that asthma treatment based
on symptom control alone might fail to suppress
bronchial hyper-responsiveness (and underlying
airway inflammation) and fail to prevent airway
remodelling,30 and this requires formal long-term
testing with a LABA in combination with an ICS.
Exacerbation rates would be a clinically relevant
measure to study, but will require more patients
and/or a longer study to demonstrate any statisti-
cally significant differences between treatment
regimens.
Further studies31,32 are currently in progress as
part of the same clinical trial programme with a
similar design to the present study; preliminary
results32 support the use of adjustable budesonide/
formoterol dosing in guided self-management over
a 6-month period.
In summary, budesonide/formoterol (Symbi-
corts) treatment rapidly achieved asthma symp-
tom control in a diverse asthma population over a
4-week period and this was maintained throughout
the remaining 3 months of the study. An adjustable-
dosing regimen with a single inhaler was as
effective as a traditional, fixed-dosing regimen in
controlling asthma and was as well tolerated at
lower overall drug dosages. Budesonide/formoterol
in a single inhaler is a logical development for
convenience and may enhance compliance by
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providing a simple, flexible, convenient, and
individualised approach to asthma management
consistent with the objectives of therapy within
the current BTS/SIGN guidelines.2 It should also
minimise the need to visit the doctor for additional
prescriptions. This study in a large, diverse patient
population has demonstrated that self-manage-
ment, based primarily on symptom parameters,
using adjustable dosing of budesonide/formoterol,
maintains improved accepted outcomes of asthma
control and patient well-being at lower overall
doses compared with fixed maintenance dosing.
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